Biomed-Lublin to build new factory
…the products Biomed will be focusing on. The rights to Lackid were sold to Polpharma a few weeks ago, but the company will continue to produce the drug on a contract basis. Biomed-Lublin plans to announce a new strategy in March 2018, Mr Pirog also revealed.
Sign up now to open the entire news item.You are allowed to open only one news item from PMR websites.
(to send requested information)
(required for new e-mails only)